埃克替尼联合沙利度胺治疗晚期非小细胞肺癌(NSCLC)临床效果及安全性分析  

Clinical efficacy and safety analysis of( NSCLC) in elderly patients with advanced non-small cell lung cancer treated with Ectini combined with thalidomide

作　　者：周海荣[1] Zhou Hai-rong(Dept.of Oncology,First Affiliated Hospital of Bengbu Medical College,Anhui 233004,China)

机构地区：[1]蚌埠医学院第一附属医院肿瘤内科,安徽蚌埠233004

出　　处：《泰山医学院学报》2019年第2期100-102,共3页Journal of Taishan Medical College

摘　　要：目的探讨埃克替尼联合沙利度胺治疗晚期非小细胞肺癌(NSCLC)临床效果及安全性。方法回顾分析2015年8月—2018年8月笔者所在医院收治的58例晚期非小细胞肺癌患者的临床资料,并随机分为观察组和对照组,观察组给予埃克替尼联合沙利度胺治疗,对照组给予埃克替尼治疗。结果观察组患者的近期总有效率、总不良反应发生率、CA125、CEA、CYFRA21-1及VEGF等指标的改善情况明显好于对照组,具有统计学差异(P <0.05)。结论埃克替尼联合沙利度胺治疗晚期非小细胞肺癌的临床疗效显著,能显著改善患者的治疗有效率,具有较好的临床安全性,是治疗晚期非小细胞肺癌的可靠方案。Objective: To investigate the clinical efficacy and safety of ectinib combined with thalidomide in the treatment of advanced non-small cell lung cancer( NSCLC). Methods: The clinical data of 58 patients with advanced non-small cell lung cancer admitted to our hospital from August 2015 to August 2018 were retrospectively analyzed. They were randomly divided into observation group and control group. Results: The short-term total effective rate,total adverse reaction rate,CA125,CEA,CYFRA21-1 and vascular endothelial growth factor in the observation group were significantly better than those in the control group( P < 0. 05). Conclusion: Ectinib combined with thalidomide in the treatment of advanced nonsmall cell lung cancer has a significant clinical effect,can significantly improve the treatment efficiency of patients with good clinical safety,is a reliable scheme for the treatment of advanced non-small cell lung cancer.

关 键 词：埃克替尼 沙利度胺 晚期非小细胞肺癌 临床效果 安全性 

分 类 号：R734.2[医药卫生—肿瘤]